Soo Chin Lee

12.5k total citations · 3 hit papers
181 papers, 5.6k citations indexed

About

Soo Chin Lee is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Soo Chin Lee has authored 181 papers receiving a total of 5.6k indexed citations (citations by other indexed papers that have themselves been cited), including 96 papers in Oncology, 53 papers in Cancer Research and 50 papers in Molecular Biology. Recurrent topics in Soo Chin Lee's work include Cancer Genomics and Diagnostics (28 papers), HER2/EGFR in Cancer Research (26 papers) and BRCA gene mutations in cancer (20 papers). Soo Chin Lee is often cited by papers focused on Cancer Genomics and Diagnostics (28 papers), HER2/EGFR in Cancer Research (26 papers) and BRCA gene mutations in cancer (20 papers). Soo Chin Lee collaborates with scholars based in Singapore, United States and Japan. Soo Chin Lee's co-authors include Chwee Teck Lim, Jongyoon Han, Boon Cher Goh, Boon-Cher Goh, Bee Luan Khoo, Majid Ebrahimi Warkiani, Ross A. Soo, Wan‐Teck Lim, Daniel Shao-Weng Tan and Ali Asgar S. Bhagat and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Soo Chin Lee

177 papers receiving 5.5k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Slanted spiral microfluidics for the ultra-fast, label-free isolation of circulating tumor cells

2013 472 citations Majid Ebrahimi Warkiani, Guofeng Guan et al. Lab on a Chip profile →
Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis

2022 284 citations Ainsley Ryan Yan Bin Lee, Louis Yi Ann Chai et al. profile →
Role of p53 in breast cancer progression: An insight into p53 targeted therapy

2023 104 citations Soo Chin Lee et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Soo Chin Lee Singapore	38	2.8k	1.6k	1.2k	913	909	181	5.6k
Sharon Marsh United States	43	3.0k 1.1×	2.9k 1.8×	708 0.6×	357 0.4×	648 0.7×	109	6.7k
Joseph Ciccolini France	36	2.4k 0.9×	1.6k 1.0×	677 0.6×	411 0.5×	683 0.8×	196	4.5k
Ann T. Farrell United States	37	2.5k 0.9×	2.8k 1.8×	631 0.5×	313 0.3×	621 0.7×	75	6.7k
Peter Nygren Sweden	47	2.7k 1.0×	2.8k 1.7×	885 0.7×	466 0.5×	768 0.8×	234	7.0k
Michael D. Green United States	39	1.8k 0.7×	1.7k 1.1×	356 0.3×	421 0.5×	1.3k 1.4×	168	6.7k
Jerry M. Collins United States	52	3.1k 1.1×	2.7k 1.7×	886 0.7×	294 0.3×	1.3k 1.4×	176	9.0k
Pingfu Fu United States	50	2.5k 0.9×	2.4k 1.5×	1.1k 0.9×	359 0.4×	2.0k 2.2×	319	8.2k
Muhammad Wasif Saif United States	44	4.6k 1.7×	1.9k 1.2×	889 0.7×	283 0.3×	1.4k 1.6×	412	7.9k
Alan V. Boddy United Kingdom	41	2.2k 0.8×	2.4k 1.5×	465 0.4×	359 0.4×	670 0.7×	188	5.9k
Étienne Chatelut France	43	2.6k 1.0×	1.8k 1.1×	389 0.3×	270 0.3×	1.0k 1.1×	234	6.6k

Countries citing papers authored by Soo Chin Lee

Since Specialization

Citations

This map shows the geographic impact of Soo Chin Lee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Soo Chin Lee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Soo Chin Lee more than expected).

Fields of papers citing papers by Soo Chin Lee

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Soo Chin Lee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Soo Chin Lee. The network helps show where Soo Chin Lee may publish in the future.

Co-authorship network of co-authors of Soo Chin Lee

This figure shows the co-authorship network connecting the top 25 collaborators of Soo Chin Lee. A scholar is included among the top collaborators of Soo Chin Lee based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Soo Chin Lee. Soo Chin Lee is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhao, Joseph J., Khi Yung Fong, Yiong Huak Chan, et al.. (2023). Indirect Treatment Comparison of First-Line CDK4/6-Inhibitors in Post-Menopausal Patients with HR+/HER2− Metastatic Breast Cancer. Cancers. 15(18). 4558–4558. 5 indexed citations

Chiu, Joanne, Soo Chin Lee, Jcm Ho, et al.. (2023). Clinical Guidance on the Monitoring and Management of Trastuzumab Deruxtecan (T-DXd)-Related Adverse Events: Insights from an Asia-Pacific Multidisciplinary Panel. Drug Safety. 46(10). 927–949. 16 indexed citations

Lee, Ainsley Ryan Yan Bin, Lauren Shapiro, Astha Thakkar, et al.. (2022). Booster doses of COVID-19 vaccines for patients with haematological and solid cancer: a systematic review and individual patient data meta-analysis. European Journal of Cancer. 172. 65–75. 26 indexed citations

Lee, Soo Chin, et al.. (2020). Cost‐effectiveness of ribociclib as initial treatment for premenopausal women with advanced breast cancer in Singapore. Cancer Reports. 4(1). e1308–e1308. 6 indexed citations

Chan, Sock Hoai, Jing Xian Teo, Eliza Courtney, et al.. (2020). Investigation into the origins of an ancient BRCA1 founder mutation identified among Chinese families in Singapore. International Journal of Cancer. 148(3). 637–645. 4 indexed citations

Rangappa, Kanchugarakoppal S., Lan Ma, Tao Zhu, et al.. (2019). Inhibition of TFF3 Enhances Sensitivity—and Overcomes Acquired Resistance—to Doxorubicin in Estrogen Receptor-Positive Mammary Carcinoma. Cancers. 11(10). 1528–1528. 22 indexed citations

Ho, Peh Joo, Mikael Hartman, Sofie A. M. Gernaat, et al.. (2018). Associations between workability and patient-reported physical, psychological and social outcomes in breast cancer survivors: a cross-sectional study. Supportive Care in Cancer. 26(8). 2815–2824. 30 indexed citations

Heong, Valerie, Nicholas Syn, Nur Sabrina Sapari, et al.. (2017). Value of a molecular screening program to support clinical trial enrollment in Asian cancer patients: The Integrated Molecular Analysis of Cancer (IMAC) Study. International Journal of Cancer. 142(9). 1890–1900. 9 indexed citations

Kong, Anthony, Daniel Rea, Samreen Ahmed, et al.. (2016). Phase 1B/2 study of the HSP90 inhibitor AUY922 plus trastuzumab in metastatic HER2-positive breast cancer patients who have progressed on trastuzumab-based regimen. Oncotarget. 7(25). 37680–37692. 34 indexed citations

10.

Wang, Tingting, Supriya Srivastava, Mikael Hartman, et al.. (2016). High expression of intratumoral stromal proteins is associated with chemotherapy resistance in breast cancer. Oncotarget. 7(34). 55155–55168. 31 indexed citations

11.

Tan, Sing‐Huang, Nur Sabrina Sapari, Hui Miao, et al.. (2015). High-Throughput Mutation Profiling Changes before and 3 Weeks after Chemotherapy in Newly Diagnosed Breast Cancer Patients. PLoS ONE. 10(12). e0142466–e0142466. 20 indexed citations

12.

Wang, Lingzhi, Winnie Yeo, Jieying Amelia Lau, et al.. (2014). Correction: Glucuronidation by UGT1A1 Is the Dominant Pathway of the Metabolic Disposition of Belinostat in Liver Cancer Patients. PLoS ONE. 9(1). 1 indexed citations

13.

Warkiani, Majid Ebrahimi, Guofeng Guan, Wong Cheng Lee, et al.. (2013). Slanted spiral microfluidics for the ultra-fast, label-free isolation of circulating tumor cells. Lab on a Chip. 14(1). 128–137. 472 indexed citations breakdown →

14.

Pang, Angela, et al.. (2013). Cancer physicians’ attitude towards treatment of the elderly cancer patient in a developed Asian country. BMC Geriatrics. 13(1). 35–35. 29 indexed citations

15.

Lee, Soo Chin, et al.. (2012). Discrepancy Between Initial High Expression of Interest in Clinical Cancer Genetic Testing and Actual Low Uptake in an Asian Population. Genetic Testing and Molecular Biomarkers. 16(7). 785–793. 16 indexed citations

16.

Pang, Angela, et al.. (2011). A case of sweet’s syndrome due to 5-Azacytidine and vorinostat in a patient with NK/T cell lymphoma. Cutaneous and Ocular Toxicology. 31(1). 64–66. 4 indexed citations

17.

Soo, Ross A., Septian Hartono, Choon Hua Thng, et al.. (2009). Phase I and Biomarker Study of ABT-869, a Multiple Receptor Tyrosine Kinase Inhibitor, in Patients With Refractory Solid Malignancies. Journal of Clinical Oncology. 27(28). 4718–4726. 72 indexed citations

18.

Soo, Ross A., Ling Zhi Wang, P Y Chong, et al.. (2008). Distribution of gemcitabine pathway genotypes in ethnic Asians and their association with outcome in non-small cell lung cancer patients. Lung Cancer. 63(1). 121–127. 56 indexed citations

19.

Jada, Srinivasa Rao, Robert C. Lim, Xiaochen Shu, et al.. (2007). Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C>A polymorphisms in irinotecan‐induced neutropenia in Asian cancer patients. Cancer Science. 98(9). 1461–1467. 96 indexed citations

20.

Lee, Soo Chin, Seng Gee Lim, Ross A. Soo, et al.. (2006). Lack of somatic mutations in EGFR tyrosine kinase domain in hepatocellular and nasopharyngeal carcinoma. Pharmacogenetics and Genomics. 16(1). 73–74. 41 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact